Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,530 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis.
Advani S, Raja A, Giraldo T, Aktaş S, Lawal A, Gotor A. · Clin Exp Dermatol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis.
Rashid M, Muhammad A, Saeed E, Qureshi AA, Mubashir MM, Waqas Bin Waheed M, Yasin MA, Abdullah M, Rashid A, Zubair Z. · Clin Drug Investig · 2026 · cited 0 timesmeta-analysis, systematic review
- Pilot Study of Gallic Acid Cream as a Potential Treatment for Plaque Psoriasis.
Greenway RR, Coulter AA, Zhang D, Greenway FL. · J Med Food · 2026 · cited 0 timesrandomized controlled trial
- Topical treatments for chronic plaque psoriasis.
Le Cleach L, Afach S, Veroniki AA, Berens D, Boisvert-Huneault C, Boyle R, Chu DK, Fahim C, Guelimi R, Mason J, Salmi F, Savinova I, Sbidian E, Seeburruth D, Seguin K, Sidre C, Steriopoulos J, Tadrous M, Tarafdar N, Bednar ED, Drucker AM, Cochrane Skin. · Cochrane Database Syst Rev · 2026 · cited 2 timesOpen accesssystematic-review
- Transcriptomic meta-analysis identifies core molecular pathways in plaque psoriasis.
Torres-Moral T, Riera-Monroig J, Tell-Martí G, Gómez-Cabañes B, Bagué J, Català-Senent JF, Roig FJ, Potrony M, García-García F, Puig S. · J Eur Acad Dermatol Venereol · 2026 · cited 1 timesmeta-analysis, systematic review
- Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis.
Shami MZ, Amara S, Shimon SV, Kest I, Islam RK, Moffatt L, Lebwohl M. · J Drugs Dermatol · 2026 · cited 0 timesnetwork meta-analysis
- Efficacy and Safety of 5% Topical Caffeine Added to 0.025% Fluocinolone Acetonide Cream for Plaque Psoriasis: A Randomized Controlled Trial.
Mamizadeh H, Herizchi Ghadim H, Pourasghary S. · Psoriasis (Auckl) · 2026 · cited 0 timesOpen accessclinical trial, case reports
- Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality.
Wang Z, Zhang Z, Chen P. · Appl Health Econ Health Policy · 2026 · cited 0 timessystematic review
- Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.
Montes-de-Oca-Saucedo CR, Ghanem L, Kirmani N, Briceño-Villardaga B, Talancon-Solana AM, Salinas-Ocampo AJ, Sereno-Acevedo G, Soto-Domínguez A, Rivera-Díaz R. · BioDrugs · 2026 · cited 0 timesmeta-analysis, systematic review
- Association Between Efficacy and Pharmacokinetics of DMB-3115 and its Originator Ustekinumab in Patients with Chronic Plaque Psoriasis: An Exposure-Response Analysis.
Konishi H, Shindo T, Ishiwata K, Morita J. · Adv Ther · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials.
Xin T, Sun S, Liu Y. · Front Immunol · 2026 · cited 0 timesOpen accesscomparative study, systematic review
- Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.
Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. · Am J Clin Dermatol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Ming J, Jiang Y, Wu Q, Xiao X, Chen M. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Cai L, Chen J, Wu L, Duan X, Zhang G, Li Y, Zhang L, Qin L, Zeng T, Wang X, Wang J, Huang K, Ren H, Liu L, Ding Y, Cui Y, Shan Y, Lu J, Tao X, Chen R, Tu Y, Yan M, Zhu X, Qiao N, Meng Z, Wang Y, Cheng F, Yuan Y, Zhu J, Hu X, Guo S, Xia X, Man X, Wu Z, Chen X, Chen G, He Y, Lv D, Feng Y, Deng D, Geng S, Guo Q, Feng W, Zhu X, Liu Y, Lin B, Xia R, Yu C, Fan J, Ji M, Lei T, Yang W, Yang M, Gao Y, Li W, Jiang M, Lou J, Liu Y, Zhou C, Zhang J. · Front Immunol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, Shi Y, Wang WH, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG. · N Engl J Med · 2025 · cited 23 timesclinical trial, phase iii, multicenter study
- Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.
Han L, Qin H, Lu X, Zhang L, Li L, Han H, Wang J, Duan X, Sun D, Yang W, Ren H, Wang X, Ci C, Wang Y, Han X, Yin W, Yu C, Zhang M, Zhu J, Wu L, Meng Z, Zeng T, Wang H, Shan Y, Ding Y, Feng W, Zhang X, Zhang G, Guo Q, Cheng H, Ji C, Fang R, Dong X, Zhu X, Lei T, Yang X, Xiao R, Liu Z, Tao X, Chen R, Lou J, Liu Y, Zhang J, Xu J. · Am J Clin Dermatol · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial.
Huang K, Zhao Y, Yang C, Zhang J. · Front Immunol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Efficacy and safety of ustekinumab biosimilars for treating moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Ye Y, Liu C, Jia L, Tang X, Li Z. · Naunyn Schmiedebergs Arch Pharmacol · 2026 · cited 1 timessystematic review, network meta-analysis
- Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded clinical trial to support interchangeability.
Blauvelt A, Bagel J, Pinter A, Thaçi D, Zhou M, Cao J, Mytych DT, Chow V, Franklin J. · Br J Dermatol · 2026 · cited 0 timesmulticenter study, randomized controlled trial
- The sliding cupping therapy as an alternative strategy for treating plaque psoriasis: A randomized controlled trial.
Liu J, Guo S, Tan J, Miao M, Shi Y, Tan C, Wei Y. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Altayf A, Lateiresh M, Marwan L, Alfeetouri MY, Zouaoui Y, Elhadi M. · Int J Dermatol · 2026 · cited 3 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of fire needle therapy for plaque psoriasis: a randomized, single-blind, multicenter clinical trial.
Liu L, Sun XY, Zhao YD, Bai QS, Huang G, Hu SY, Yang YY, Xu R, Yang SQ, Gong LP, Li LE, Yan XN, Li X, Li B. · QJM · 2026 · cited 2 timesmulticenter study, randomized controlled trial
- Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
AlJuma RS, Hashim S, Alshamali MA, Alkhatlan S, Hammadi DJ, Alharran AM. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. · JAMA Dermatol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.
Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin M, Sauder M, Gerdes S, Reyes-Servin O, Edem BE, Campbell J, Cresswell K, Kephart L, Li S, Yang YW, Bissonnette R. · Br J Dermatol · 2026 · cited 2 timesclinical trial, phase iii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.